DOW JONES27,960.80+0.00 0.00%
S&P 5003,225.89+0.00 0.00%
NASDAQ9,268.46+47.18 0.51%

UPDATE: Acasti Postpones Topline Results For TRILOGY 1 Phase 3 Trial Of CaPre From Dec. 2019 To Jan. 2020, Cites 'unexpected delay in data processing, transfer from central testing labs to statistical consultants for independent, external validation'

Benzinga · 12/24/2019 12:11